In cats, in vitro experiments on injection-site sarcoma cell lines demonstrated dose-dependent cytotoxicity independent of mTOR inhibition [40], and a pilot dose-escalation clinical trial in tumour-bearing cats identified gastrointestinal toxicity and hyperlactatemia as dose-limiting, with a maximum tolerated dose of 10 mg/kg q12h [41] (Table 1). The gene discussed is MTOR; the disease is neoplasm.